Imunon, Inc. · NASDAQ:IMNN

Imunon — Zacks SCR Life Sciences Virtual Investor Forum (June 2026)

18 slides from Imunon's conference presentation, Jun 25, 2026

  1. Slide 1: Developing medicines harnessing the capability of DNA to power body's immune system

    Developing medicines harnessing the capability of DNA to power body’s Stacy R. Lindborg, Ph.D. immune system President & CEO Zacks SCR Life Sciences Virtual Investor Forum June 25, 2026 Nasdaq: IMNN © 2024 IMUNON, Inc. PAGE 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Imunon, Inc. (“IMUNON” or the “Company”) or any person on their behalf, any question-and-a

  3. Slide 3: Investment Thesis

    Investment Thesis Funding IMNN-001 IL-12 Registrational Study for 1st line Ovarian Cancer • First-in-Class Immunotherapy with proven safety profile and unprecedented efficacy data in a randomized, well controlled Phase 2 in newly diagnosed ovarian cancer population • Data driven registrational study

  4. Slide 4: Background

    4 Background Immune approaches in EOC IMNN-001: MoA IMNN-001: Local IP delivery  IMNN-001 is a novel IL-12 DNA-mediated  IMNN-001 is an IL-12 DNA-based plasmid  Immunotherapy is considered an attractive therapy investigational product encased in a lipopolymer nanoparticle delivery approach for th

  5. Slide 5: IL-12 Immunotherapy: Renewing the Elusive Promise for Ovarian Cancer Survival

    IL-12 Immunotherapy: Renewing the Elusive Promise for Ovarian Cancer Survival Ovarian Cancer is an immunosuppressive cancer and IL-12 is one of the most powerful anti-tumor cytokines. IMNN-001 approached it differently Over the last 25 years there have been many challenges based on systemically dosi

  6. Slide 6: Product Pipeline of DNA-based Transformative Medicines

    Product Pipeline of DNA-based Transformative Medicines Platform Delivery Program Indication(s) Discovery IND Phase 1 Phase 2 Phase 3 enabling Partner Newly Diagnosed Adv. IL-12 (OVATION 3) IMNN-001 enrolling Ovarian Cancer IL-12 in combination with Newly Diagnosed Adv. Avastin* Ovarian Cancer IMNN-0

  7. Slide 7: Great Unmet Need: Patient Outcomes and Frontline Standard of Care Unchanged for 30 years

    Great Unmet Need: Patient Outcomes and Frontline Standard of Care Unchanged for 30 years Recurrence Rates are High and Survival Rates are Low Epithelial ovarian cancer (EOC) is insidious and usually diagnosed at an advanced stage. Though EOC initially responds to treatment, the recurrence rate is hi

  8. Slide 8: IMNN-001: A Potential Breakthrough in Newly Diagnosed Ovarian Cancer

    IMNN-001: A Potential Breakthrough in Newly Diagnosed Ovarian Cancer No other frontline ovarian cancer trial has shown an OS improvement; IMNN-001 has a highly favorable benefit/risk profile IMNN-001 may be the 1st immuno-therapy for ovarian cancer, with the potential to transform the standard of ca

  9. Slide 9: IMNN-001 Continues to Have a Highly Favorable Benefit/Risk Profile Through Phase 2

    IMNN-001 Continues to Have a Highly Favorable Benefit/Risk Profile Through Phase 2 OVATION 2, Phase 2: key safety observations • No systemic dose limiting toxicities associated with IV administration of IL-12 were observed • Cytokine release syndrome (CRS) did not occur with IMNN-001 treatment • No

  10. Slide 10: IMNN-001: Demonstrating the Ability to Fundamentally Alter the Tumor Microenvironment

    IMNN-001: Demonstrating the Ability to Fundamentally Alter the Tumor Microenvironment Checkpoint Inhibitors (ICIs) have been unsuccessful in Decrease in Immunosuppressive Biomarkers in Tumor impacting overall survival; ICIs cannot target a “cold tumor” 0% 10 FoxP3 IDO-1 PD-1 PD-L1 CA 125 % 20 % IMNN

  11. Slide 11: IMNN-001 Has a Broad Impact on the Tumor Microenvironment

    IMNN-001 Has a Broad Impact on the Tumor Microenvironment Translational Data Sampling Confirms 100 mg/m2 as the Phase 3 dose IMNN-001 dose-dependent and local selective expression of IL-12 and IFN-γ levels in patients’ samples  Increases in cytokine levels at tumor site show IMNN-001 OVATION-1 OVAT

  12. Slide 12: OVATION 2 Data Show Continued IMNN-001 Overall Survival Improvement

    OVATION 2 Data Show Continued IMNN-001 Overall Survival Improvement ITT, all-comers population: July 2024 ∆medians 11.1 months → Final Analysis: ∆medians 14.7 months Median OS: 45.1 mo IMNN+NACT, 30.4 mo NACT Difference, 95% CI: 14.8 (-3.8, 33.3), one-sided p-value = 0.056 Modified Weighted Log Rank

  13. Slide 13: OVATION 2 PARPi-Treated Show 24-month IMNN-001 Overall Survival Improvement

    OVATION 2 PARPi-Treated Show 24-month IMNN-001 Overall Survival Improvement PARPi maintenance treated patients: July 2024 ∆medians not evaluable → Final Analysis: ∆medians 24.2 months Median OS: 65.6 mo IMNN+NACT, 41.4 mo NACT, Difference 24.2 mo* Modified Weighted Log Rank, one-sided p-value = 0.18

  14. Slide 14: Our Phase 2 Clinical Research is of Great Importance to the Medical Community

    14 Our Phase 3 Clinical Research is of Great Importance to the Medical Community • Our Landmark Phase 2 Study was Showcased at ASCO with a Platform Presentation • Published in Gynecologic Oncology, Premier Medical Outlets © 2024 IMUNON, Inc. PAGE 14

  15. Slide 15: OVATION 2 Treatment Effect Consistently Favors IMNN-001 Across All Trial Endpoints and Subgroups

    OVATION 2 Treatment Effect Consistently Favors IMNN-001 Across All Trial Endpoints and Pre-specified Subgroups† Consistent treatment effect in ongoing Phase 2 MRD Trial*: • Lower MRD-positivity rate • Lower % of positive biopsies • Higher Progression Free Survival • Higher CRS at cytoreduction † Tha

  16. Slide 16: OVATION 3: Purposeful Protocol Design & Rigorous Methodology

    OVATION 3: Purposeful Protocol Design & Rigorous Methodology Frontline Therapy Maintenance Therapy Laparoscopy NACT (3 cycles) + ACT (3 cycles) + PARPi treatment: HRD Interval Debulking Surgery IMNN-001 (weekly) IMNN-0 0 1 (weekly) participants only N=500 Stage IIIB/C or IV EOT visit EOC patients R

  17. Slide 17: IMUNON in Phase 3, Well Positioned with Early Stopping Potential

    IMUNON in Phase 3, Well Positioned with Early Stopping Potential • Robust Data from 112 patient OVATION-2 (Phase 2) demonstrating IMNN-001 improvement over SoC • Confidence in Phase 3 trial based on consistency of clinical data across all endpoints and subgroups • Final Data validated continued OS b

  18. Slide 18: Corporate Information

    Corporate Information Headquarters Research Facility Princeton, NJ Huntsville, AL IMUNON P: 609-896-9100 997 Lenox Drive F: 609-896-2200 Suite 100 Lawrenceville, NJ 08648 www.imunon.com Nasdaq: IMNN © 2024 IMUNON, Inc. PAGE 18

Imunon — Zacks SCR Life Sciences Virtual Investor Forum (June 2026) on 6ix